A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label (doctors and patients know which drug will be given), single center,
phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides
benefit to patients with previously untreated indolent non-Hodgkin's lymphomas (NHL).